Twenty more states have joined a Connecticut-led antitrust lawsuit accusing six generic drugmakers of price manipulation and other anti-competitive behavior, state Attorney General George Jepsen said Wednesday.
Originally filed in December, the suit had 20 state attorneys general as plaintiffs. On Wednesday, Jepsen filed an amended complaint that adds 20 more states.
Defendants include Aurobindo Pharma USA, Citron Pharma LLC, Heritage Pharmaceuticals, Mayne Pharma USA, Mylan Pharmaceuticals and Teva Pharmaceuticals.
“Today’s amended complaint is, I believe, a testament to the strength of this case and the importance of this investigation,” Jepsen said in a statement. “The anticompetitive actions that we allege in this complaint are egregious and, ultimately, consumers, businesses and taxpayers paid the price.”
The suit was the result of a state investigation into rising generic drug prices that began in 2014.
That investigation is still ongoing, Jepsen said, which is why some information in court documents is redacted.
DOWNLOAD PDFs
